3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 4
1
Status
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Breast Neoplasms
555
Carcinoma, Non-Small-Cell Lung
507
Prostatic Neoplasms
330
Neoplasms
268
Multiple Myeloma
266
Colorectal Neoplasms
264
Leukemia, Myeloid, Acute
225
Squamous Cell Carcinoma of Head and Neck
216
Lung Neoplasms
209
Neoplasm Metastasis
203
Carcinoma, Hepatocellular
195
Triple Negative Breast Neoplasms
172
Melanoma
172
Pancreatic Neoplasms
170
Ovarian Neoplasms
150
Recurrence
148
Lymphoma
143
Glioblastoma
134
Brain Neoplasms
133
Sarcoma
128
Leukemia, Lymphocytic, Chronic, B-Cell
127
Carcinoma, Renal Cell
127
Lymphoma, Large B-Cell, Diffuse
125
Stomach Neoplasms
124
Head and Neck Neoplasms
120
Precursor Cell Lymphoblastic Leukemia-Lymphoma
110
Rectal Neoplasms
107
Myelodysplastic Syndromes
105
Urinary Bladder Neoplasms
100
Small Cell Lung Carcinoma
98
Interventions
Triamcinolone Acetonide
1
TH 302
1
Injections, Intramuscular
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Castration Resistant Prostate Cancer
×
1 year
×
Clear all
NCT06836726
2026-01-28
EVO
University Health Network, Toronto
Phase 2
Not yet recruiting
35 enrolled
NCT07161778
2025-09-09
TRICREST
Barts & The London NHS Trust
Phase 2
Completed
55 enrolled